International mRNA Vaccine Trailblazers Katalin Karikó and Drew Weissman Raking Up Prestigious Awards in Medicine

Arkain2K

Si vis pacem, para bellum
@Steel
Joined
Dec 6, 2010
Messages
33,420
Reaction score
5,681
Dr. Katalin Karikó Awarded Swiss Academy's Reichstein Medal, Nobel Prize on the Horizon?
By Tamás Vaski | 2021.06.21​



Katalin Karikó is the recipient of this summer year’s Reichstein Medal, the most prestigious Swiss award in the field of medicine. The recognition by the Swiss Academy of Pharmaceutical Sciences hints at the Hungarian biochemist’s increasing odds of receiving a Nobel Prize.

Thanks to her decades of work in pioneering mRNA vaccine technology, Katalin Karikó is receiving one prestigious award after another. The well-deserved recognition is recent, however, since she did not see much support during the 80s and 90s, when colleagues even attempted to dissuade her from her goal.

Now in 2021, Karikó has received the greatest Hungarian scientific award, the Széchényi Prize, as well as the Rosenstiel Award along with Drew Weissman.

But what should be noted about the Reichstein Medal is that it has often been followed with a Nobel Prize as well. The suspicion of one for Karikó has been on the table for a while, but now her chances are becoming even more clear.

The official statement of the Swiss Academy emphasizes that “Katalin Karikó’s contributions to mRNA research and its use in vaccines and medicine are fundamental.”

"Your determination in the development of this new technology did not only bring a new age to vaccinology, but it contributed to quick and mass-level immunizations, which prevented the continued spread of Covid.”

The Reichstein Medal, named after the Polish-Swiss Nobel Prize-winning chemist Tadeusz Reichstein, is awarded by the Swiss Academy to internationally recognized scientists who contributed immensely to the field of medicine through research, education, and practical applications.

When handing over the award, President of the Swiss Academy Gerrit Borchard said that “the example set by Katalin Karikó proves the yield which society can benefit from following at-times lengthy academic endeavors.”

https://hungarytoday.hu/katalin-kariko-nobel-prize-reichstein-medal-2021/
 
Last edited:
This piece explain why there is such a long stagnation in scientific research compare to tech: One field contantly rewards funding to innovative disruptors with groundbreaking ideas, while the other regressed to "safe investments" on old ideas that's more likely to make short-term profits.
The Science Funding Crisis That Nearly Killed mRNA Vaccine Development
By Julie Heng | The Harvard Crimson | March 15, 2021​

Last year, scientists developed mRNA Covid-19 vaccines at historic speed. That wouldn’t have happened if it weren’t for scientists like Katalin Kariko, who has laid the groundwork for mRNA vaccine development since the 1990s.

Kariko’s own career, however, nearly ended in 1995, and her story shows how science funding mechanisms in the U.S. have failed us.

After arriving in the U.S. from Hungary, Kariko sought to develop therapies using mRNA, pieces of genetic code that tell cells what proteins to make. Theoretically, you could artificially create mRNA that encoded instructions for enzymes or antibodies. Practically, however, it was a challenge to send synthetic mRNA into the body’s cells in the first place, and most scientists abandoned the field.

Not Kariko. Kariko sent out countless grant applications and received countless rejections in her pursuit of developing mRNA technology, and with no money coming in, the University of Pennsylvania demoted her.

At this point, with their reputation skewered, most scientists would let go of their research. But Kariko, despite being newly diagnosed with cancer, pressed on. From when Kariko was demoted from the University of Pennsylvania in 1995 to when she was kicked out of the lab in 2013, her salary barely changed, even as health insurance and parking costs went up — she was making less than the lab technicians she worked with.

“I could see that people around me, you know, they get the grants and they get the money,” Kariko said in an interview. She was never awarded a single major grant from the National Institutes of Health over the course of her career.

As I was talking to Kariko over Zoom, it was obvious how passionate she is about science. She told me about her excitement heading into the lab at 6 a.m. on Sundays.

“There's people from outside seeing me struggling or sweating. The whole thing is struggle, struggle,” Kariko told me. But “as long as you could see how [your research was] advancing, you didn't feel tiredness.”

I am in awe of Kariko’s service to science and her relentless determination despite countless grant rejections, not to mention demotion. But the fact stands: The system failed to support mRNA research, and most researchers would have pivoted.

“It's a complicated ecosystem,” Harvard Dean of Science Christopher Stubbs said in an interview with the Crimson. “People move their research in the direction where the resources exist for sure.”

Current grant funding can come from either private companies and foundations or the government. Funding in the public arena began after World War II, and the selection process has since greatly intensified. Individual researchers submit proposals to a government agency like the National Science Foundation or NIH, where a group of scientists evaluate the proposals and allocate funding to only about 10 percent of proposals. The National Cancer Institute’s funding line is even lower.

What this means is that current scientific research follows a “regression to the mean instead of aspiration to excellence,” according to Astronomy professor Avi Loeb. Since a vast majority of applications are rejected, funding mechanisms end up driving many researchers into non-academic positions or leaving many researchers in the field spending time writing grants and chasing more conservative trends, performing minor variations on trending or already-successful research experiments.

“Extraordinary conservatism leads to extraordinary ignorance,” said Loeb, who faced skepticism and ridicule from colleagues for hypothesizing that ʻOumuamua was an interstellar extraterrestrial object. “Because if you are not open-minded to discover new things, you will never find them.”

Most grant proposals ask for a breakdown of what you hope to accomplish in year one, two, and three. What’s backwards about this procedure is that the grant mechanism itself projects and ensures an expectation of what you’re hoping to accomplish. In fact, many researchers apply for grants having already finished half or most of the project.

Loeb recalled once submitting what he considered a “safe” grant proposal — a project he had already completed and slated for publication, only to receive a grant rejection that claimed the project could not be done.

“I feel like I'm serving the role of the kid saying the emperor has no clothes,” Loeb said. “I hate it when some of my colleagues are basically speaking responsibly: keeping an image and never making mistakes, and having their students and postdocs repeat what they did already and just making it even louder.”

So, how do we solve the funding issue? For one, we must increase funding overall to combat the scarcity and constraint of funding lines. More importantly, we must foster innovative research by specifically portioning funds for high-risk projects.

Kariko told me that despite every obstacle, she was driven from within by a love of science: “I don’t use a stick or carrot.” But many scientists in Kariko’s position, frustrated that available funding mechanisms did not recognize the importance of their work, would have given up. Furthermore, mRNA was intellectually interesting to Kariko, but nobody knew just how important it would be to humanity in 2020. If we fund projects that only advertise immediate and obvious benefits, then we’re shooting ourselves in the foot.

It is also paramount to make sure that these high-risk funds aren’t only given to established labs that have already made it and been winnowed out — perhaps, every lab should be given a chance to try one potentially major project.

At the end of the day, funding is supposed to fuel science, not hinder it. If the funding system is actively preventing groundbreaking research, we have to change that system.

https://www.thecrimson.com/column/t...rticle/2021/3/15/heng-science-funding-crisis/
 
Last edited:
The story of mRNA: How a once-dismissed idea became a leading technology in the Covid vaccine race

Before messenger RNA was a multibillion-dollar idea, it was a scientific backwater. And for the Hungarian-born scientist behind a key mRNA discovery, it was a career dead-end.

Katalin Karikó spent the 1990s collecting rejections. Her work, attempting to harness the power of mRNA to fight disease, was too far-fetched for government grants, corporate funding, and even support from her own colleagues...

https://www.statnews.com/2020/11/10...leading-technology-in-the-covid-vaccine-race/
 
Kati Kariko Helped Shield the World From the Coronavirus
By Gina Kolata | April 8, 2021​

00virus-kariko-1-facebookJumbo.jpg

She grew up in Hungary, daughter of a butcher. She determined she needed to be a scientist, though she had by no means met one. She moved to the United States in her 20s, however for many years by no means discovered a everlasting place, as an alternative clinging to the fringes of academia.

Now Katalin Kariko, 66, identified to colleagues as Kati, has emerged as one of many heroes of Covid-19 vaccine improvement. Her work, together with her shut collaborator, Dr. Drew Weissman of the University of Pennsylvania, laid the inspiration for the stunningly profitable vaccines made by Pfizer-BioNTech and Moderna.

For her total profession, Dr. Kariko has centered on messenger RNA, or mRNA — the genetic script that carries DNA directions to every cell’s protein-making equipment. She was satisfied mRNA could possibly be used to instruct cells to make their very own medicines, together with vaccines.

But for a few years her profession on the University of Pennsylvania was fragile. She migrated from lab to lab, counting on one senior scientist after one other to take her in. She by no means made greater than $60,000 a 12 months.

By all accounts intense and single-minded, Dr. Kariko lives for “the bench” — the spot within the lab the place she works. She cares little for fame. “The bench is there, the science is good,” she shrugged in a latest interview. “Who cares?”

Dr. Anthony Fauci, director of the National Institutes of Allergy and infectious Diseases, is aware of Dr. Kariko’s work. “She was, in a positive sense, kind of obsessed with the concept of messenger RNA,” he mentioned.

Dr. Kariko’s struggles to remain afloat in academia have a well-known ring to scientists. She wanted grants to pursue concepts that appeared wild and fanciful. She didn’t get them, at the same time as extra mundane analysis was rewarded.

“When your idea is against the conventional wisdom that makes sense to the star chamber, it is very hard to break out,” mentioned Dr. David Langer, a neurosurgeon who has labored with Dr. Kariko.

Dr. Kariko’s concepts about mRNA had been positively unorthodox. Increasingly, additionally they appear to have been prescient.

“It’s going to be transforming,” Dr. Fauci mentioned of mRNA analysis. “It is already transforming for Covid-19, but also for other vaccines. H.I.V. — people in the field are already excited. Influenza, malaria.”

For Dr. Kariko, most daily was a day within the lab. “You are not going to work — you are going to have fun,” her husband, Bela Francia, supervisor of an house complicated, used to inform her as she dashed again to the workplace on evenings and weekends. He as soon as calculated that her infinite workdays meant she was incomes a few greenback an hour.

For many scientists, a brand new discovery is adopted by a plan to generate profits, to kind an organization and get a patent. But not for Dr. Kariko. “That’s the furthest thing from Kate’s mind,” Dr. Langer mentioned.

She grew up within the small Hungarian city of Kisujszallas. She earned a Ph.D. on the University of Szeged and labored as a postdoctoral fellow at its Biological Research Center.

In 1985, when the college’s analysis program ran out of cash, Dr. Kariko, her husband, and 2-year-old daughter, Susan, moved to Philadelphia for a job as a postdoctoral pupil at Temple University. Because the Hungarian authorities solely allowed them to take $100 overseas, she and her husband sewed £900 (roughly $1,246 in the present day) into Susan’s teddy bear. (Susan grew as much as be a two-time Olympic gold medal winner in rowing.)

When Dr. Kariko began, it was early days within the mRNA subject. Even essentially the most primary duties had been troublesome, if not not possible. How do you make RNA molecules in a lab? How do you get mRNA into cells of the physique?

In 1989, she landed a job with Dr. Elliot Barnathan, then a heart specialist on the University of Pennsylvania. It was a low-level place, analysis assistant professor, and by no means meant to result in a everlasting tenured place. She was purported to be supported by grant cash, however none got here in.

She and Dr. Barnathan deliberate to insert mRNA into cells, inducing them to make new proteins. In one of many first experiments, they hoped to make use of the technique to instruct cells to make a protein known as the urokinase receptor. If the experiment labored, they might detect the brand new protein with a radioactive molecule that might be drawn to the receptor.

“Most people laughed at us,” Dr. Barnathan mentioned.

One fateful day, the 2 scientists hovered over a dot-matrix printer in a slim room on the finish of an extended corridor. A gamma counter, wanted to trace the radioactive molecule, was hooked up to a printer. It started to spew knowledge.

Their detector had discovered new proteins produced by cells that had been by no means purported to make them — suggesting that mRNA could possibly be used to direct any cell to make any protein, at will.

“I felt like a god,” Dr. Kariko recalled.

She and Dr. Barnathan had been on hearth with concepts. Maybe they may use mRNA to enhance blood vessels for coronary heart bypass surgical procedure. Perhaps they may even use the process to increase the life span of human cells.

Dr. Barnathan, although, quickly left the college, accepting a place at a biotech agency, and Dr. Kariko was left with no lab or monetary help. She may keep at Penn provided that she discovered one other lab to take her on. “They expected I would quit,” she mentioned.

Universities solely help low-level Ph.D.s for a restricted period of time, Dr. Langer mentioned: “If they don’t get a grant, they will let them go.” Dr. Kariko “was not a great grant writer,” and at that time “mRNA was more of an idea,” he mentioned.

But Dr. Langer knew Dr. Kariko from his days as a medical resident, when he had labored in Dr. Barnathan’s lab. Dr. Langer urged the top of the neurosurgery division to provide Dr. Kariko’s analysis an opportunity. “He saved me,” she mentioned.

Dr. Langer thinks it was Dr. Kariko who saved him — from the form of pondering that dooms so many scientists.

Working together with her, he realized that one key to actual scientific understanding is to design experiments that all the time inform you one thing, even whether it is one thing you don’t wish to hear. The essential knowledge typically come from the management, he discovered — the a part of the experiment that includes a dummy substance for comparability.

“There’s a tendency when scientists are looking at data to try to validate their own idea,” Dr. Langer mentioned. “The best scientists try to prove themselves wrong. Kate’s genius was a willingness to accept failure and keep trying, and her ability to answer questions people were not smart enough to ask.”

Dr. Langer hoped to make use of mRNA to deal with sufferers who developed blood clots following mind surgical procedure, typically leading to strokes. His thought was to get cells in blood vessels to make nitric oxide, a substance that dilates blood vessels, however has a half-life of milliseconds. Doctors can’t simply inject sufferers with it.

He and Dr. Kariko tried their mRNA on remoted blood vessels used to review strokes. It failed. They trudged by snow in Buffalo, N.Y., to attempt it in a laboratory with rabbits susceptible to strokes. Failure once more.

After which Dr. Langer left the college, and the division chairman stated he was leaving as properly. Dr. Kariko once more was with no lab and with out funds for analysis.

A gathering at a photocopying machine modified that. Dr. Weissman occurred by, and he or she struck up a dialog. “I stated, ‘I’m an RNA scientist — I could make something with mRNA,’” Dr. Kariko recalled.

Dr. Weissman instructed her he needed to make a vaccine in opposition to H.I.V. “I stated, ‘Yeah, yeah, I can do it,’” Dr. Kariko stated.

Regardless of her bravado, her analysis on mRNA had stalled. She may make mRNA molecules that instructed cells in petri dishes to make the protein of her selection. However the mRNA didn’t work in dwelling mice.

“No person knew why,” Dr. Weissman stated. “All we knew was that the mice acquired sick. Their fur acquired ruffled, they hunched up, they stopped consuming, they stopped working.”

It turned out that the immune system acknowledges invading microbes by detecting their mRNA and responding with irritation. The scientists’ mRNA injections regarded to the immune system like an invasion of pathogens.

However with that reply got here one other puzzle. Each cell in each particular person’s physique makes mRNA, and the immune system turns a blind eye. “Why is the mRNA I made totally different?” Dr. Kariko puzzled.

A management in an experiment lastly offered a clue. Dr. Kariko and Dr. Weissman observed their mRNA prompted an immune overreaction. However the management molecules, one other type of RNA within the human physique — so-called switch RNA, or tRNA — didn’t.

A molecule known as pseudouridine in tRNA allowed it to evade the immune response. Because it turned out, naturally occurring human mRNA additionally accommodates the molecule.

Added to the mRNA made by Dr. Kariko and Dr. Weissman, the molecule did the identical — and in addition made the mRNA rather more highly effective, directing the synthesis of 10 instances as a lot protein in every cell.

The concept that including pseudouridine to mRNA protected it from the physique’s immune system was a primary scientific discovery with a variety of thrilling functions. It meant that mRNA may very well be used to change the capabilities of cells with out prompting an immune system assault.

“We each began writing grants,” Dr. Weissman stated. “We didn’t get most of them. Folks weren’t all for mRNA. The individuals who reviewed the grants stated mRNA won’t be an excellent therapeutic, so don’t hassle.’”

Main scientific journals rejected their work. When the analysis lastly was published, in Immunity, it acquired little consideration.

Dr. Weissman and Dr. Kariko then confirmed they may induce an animal — a monkey — to make a protein they’d chosen. In this case, they injected monkeys with mRNA for erythropoietin, a protein that stimulates the physique to make crimson blood cells. The animals’ crimson blood cell counts soared.

The scientists thought the identical methodology could possibly be used to immediate the physique to make any protein drug, like insulin or different hormones or a number of the new diabetes medicine. Crucially, mRNA additionally could possibly be used to make vaccines in contrast to any seen earlier than.

Instead of injecting a bit of a virus into the physique, docs may inject mRNA that might instruct cells to briefly make that a part of the virus.

“We talked to pharmaceutical companies and venture capitalists. No one cared,” Dr. Weissman mentioned. “We were screaming a lot, but no one would listen.”

Eventually, although, two biotech corporations took discover of the work: Moderna, within the United States, and BioNTech, in Germany. Pfizer partnered with BioNTech, and the 2 now assist fund Dr. Weissman’s lab.

Soon scientific trials of an mRNA flu vaccine had been underway, and there have been efforts to construct new vaccines towards cytomegalovirus and the Zika virus, amongst others. Then got here the coronavirus.

Researchers had identified for 20 years that the essential function of any coronavirus is the spike protein sitting on its floor, which permits the virus to inject itself into human cells. It was a fats goal for an mRNA vaccine.

Chinese scientists posted the genetic sequence of the virus ravaging Wuhan in January 2020, and researchers in all places went to work. BioNTech designed its mRNA vaccine in hours; Moderna designed its in two days.

The vaccines, although, wanted a lipid bubble to encase the mRNA and carry it to the cells that it might enter. The car got here rapidly, based mostly on 25 years of work by a number of scientists, together with Pieter Cullis of the University of British Columbia.

Scientists additionally wanted to isolate the virus’s spike protein from the bounty of genetic knowledge supplied by Chinese researchers. Dr. Barney Graham, of the National Institutes of Health, and Jason McClellan, of the University of Texas at Austin, solved that downside in brief order.

Testing the rapidly designed vaccines required a monumental effort by corporations and the National Institutes of Health. But Dr. Kariko had no doubts.

On Nov. 8, the primary outcomes of the Pfizer-BioNTech examine got here in, exhibiting that the mRNA vaccine provided highly effective immunity to the brand new virus. Dr. Kariko turned to her husband. “Oh, it works,” she mentioned. “I thought so.”

To have fun, she ate a whole field of Goobers chocolate-covered peanuts. By herself.

Dr. Weissman celebrated together with his household, ordering takeout dinner from an Italian restaurant, “with wine,” he mentioned. Deep down, he was awed.

“My dream was always that we develop something in the lab that helps people,” Dr. Weissman mentioned. “I’ve satisfied my life’s dream.”

Dr. Kariko and Dr. Weissman had been vaccinated on Dec. 18 on the University of Pennsylvania. Their inoculations was a press occasion, and because the cameras flashed, she started to really feel uncharacteristically overwhelmed.

A senior administrator informed the docs and nurses rolling up their sleeves for pictures that the scientists whose analysis made the vaccine doable had been current, they usually all clapped. Dr. Kariko wept.

Things may have gone so otherwise, for the scientists and for the world, Dr. Langer mentioned. “There are probably many people like her who failed,” he mentioned.

https://www.nytimes.com/2021/04/08/health/coronavirus-mrna-kariko.html
 
Last edited:
Dr. Katalin Karikó Awarded Swiss Academy's Reichstein Medal, Nobel Prize on the Horizon?
By Tamás Vaski | 2021.06.21​



Katalin Karikó is the recipient of this summer year’s Reichstein Medal, the most prestigious Swiss award in the field of medicine. The recognition by the Swiss Academy of Pharmaceutical Sciences hints at the Hungarian biochemist’s increasing odds of receiving a Nobel Prize.

Thanks to her decades of work in pioneering mRNA vaccine technology, Katalin Karikó is receiving one prestigious award after another. The well-deserved recognition is recent, however, since she did not see much support during the 80s and 90s, when colleagues even attempted to dissuade her from her goal.

Now in 2021, Karikó has received the greatest Hungarian scientific award, the Széchényi Prize, as well as the Rosenstiel Award along with Drew Weissman.

But what should be noted about the Reichstein Medal is that it has often been followed with a Nobel Prize as well. The suspicion of one for Karikó has been on the table for a while, but now her chances are becoming even more clear.

The official statement of the Swiss Academy emphasizes that “Katalin Karikó’s contributions to mRNA research and its use in vaccines and medicine are fundamental.”

"Your determination in the development of this new technology did not only bring a new age to vaccinology, but it contributed to quick and mass-level immunizations, which prevented the continued spread of Covid.”

The Reichstein Medal, named after the Polish-Swiss Nobel Prize-winning chemist Tadeusz Reichstein, is awarded by the Swiss Academy to internationally recognized scientists who contributed immensely to the field of medicine through research, education, and practical applications.

When handing over the award, President of the Swiss Academy Gerrit Borchard said that “the example set by Katalin Karikó proves the yield which society can benefit from following at-times lengthy academic endeavors.”

https://hungarytoday.hu/katalin-kariko-nobel-prize-reichstein-medal-2021/


She’ll be remember with the likes of Jonas Salk.
 
They should probably hold off on the award until 5 year animal trials and 2 year human trials are completed on this new drug

It's not for this specific drug. It's for a decade + of work on mRNA vaccine technology. The vaccine for Covid 19 is not the first mRNA vaccine to exist.
 
It's not for this specific drug. It's for a decade + of work on mRNA vaccine technology. The vaccine for Covid 19 is not the first mRNA vaccine to exist.
Why are you even replying to that guy?
 
What an inspiring story.

Makes you wonder how many other potential scientific innovations got passed up for research grants and laments in the lab basements across the country because there's no guarantee for immediate ROI in revolutionary scientific ideas.
 
University of Pennsylvania mRNA Pioneers Awarded Spain's Princess of Asturias Award
Drew Weissman and Katalin Karikó receive prestigious honor for their foundational research that led to development of two lifesaving mRNA COVID-19 vaccines
June 24, 2021

weissman_kariko.ashx

Drew Weissman, MD, PhD, and Katalin Karikó, PhD​

PHILADELPHIA – Drew Weissman, MD, PhD, and Katalin Karikó, PhD, the pair of researchers from the Perelman School of Medicine at the University of Pennsylvania whose innovative mRNA research laid the foundation for development of the COVID-19 mRNA vaccines being deployed across the globe, have been named among recipients of the 2021 Princess of Asturias Award for Technical and Scientific Research.

The honor, from the Princess of Asturias Foundation (Fundación Princesa de Asturias), a Spanish non-profit organization, is conferred to individuals and organizations whose work makes significant contributions to humanity through scientific, technical, cultural, social and humanitarian work. Winners receive a prize of 50,000 Euros, and the recognition will be officially bestowed in October 2021 in Oviedo, Spain, during a ceremony presided over by their Majesties King Felipe and Queen Letizia of Spain, accompanied by HRH Princess of Asturias Leonor.

Weissman, the Roberts Family Professor of Vaccine Research in the Perelman School of Medicine at the University of Pennsylvania, and Karikó, an adjunct professor of Neurosurgery at the Perelman School of Medicine at Penn and a senior vice president at BioNTech, published research in 2005 showing how to specifically alter one of the building blocks of mRNA in order to increase its therapeutic potential. These findings and other mRNA discoveries from the two scientists, including how to effectively deliver mRNA using vaccination, were crucial to the development of the COVID-19 mRNA vaccines created by BioNTech/Pfizer and Moderna.

“We are proud of Dr. Weissman’s and Dr. Kariko’s monumental achievements in mRNA science and congratulate them on this outstanding honor, which is a fitting recognition of the global impact of their commitment to innovative, lifesaving science,” said J. Larry Jameson, MD, PhD, executive vice president of the University of Pennsylvania for the Health System and the dean of the Perelman School of Medicine. “Their accomplishments in labs at Penn are exemplars of scientific efforts that begin with bold ideas and go on, through time and intensive vision and fortitude, to change the world.”

This year’s other recipients of the Princess of Asturias Award include Philip Felgner, Uğur Şahin, Özlem Türeci, Derrick Rossi and Sarah Gilbert, each of whom have independently contributed to the development of some of the COVID-19 vaccines in use to fight the pandemic across the world.

The Princess of Asturias Foundation, established in 1980, as a private non-profit institution whose essential aims are to contribute to extolling and promoting those scientific, cultural and humanistic values that form part of the universal heritage of humanity and consolidate the existing links between the Principality of Asturias and the title traditionally held by the heirs to the Crown of Spain. The heir to the Crown, Her Royal Highness The Princess Leonor de Borbón y Ortiz, serves as the current honorary president of the organization.

https://www.pennmedicine.org/news/n...oneers-awarded-the-princess-of-asturias-award
 
Penn Medicine establishes professorship, fellowship for vaccine research and development
By Enrique Roces 08/09/21

fc67b2fb-7994-4e0a-b40a-71bd2d59ce0a.sized-1000x1000.jpg

The Perelman School of Medicine announced a new fellowship and professorship dedicated to vaccine research and development.

The Aileen and Brian Roberts foundation will fund the Roberts Family Professorship in Vaccine Research and the Katalin Karikó Fellowship Fund in Vaccine Development to “further cement Penn as a home for mRNA research,” Penn Medicine News reported.

“Penn has long been at the forefront of cutting-edge research and technology advances, and its discovery of RNA-based vaccines is another incredible achievement for the institution and the city of Philadelphia,” Aileen and Brian Roberts told Penn Medicine News. “It is our family’s privilege to support the life-changing research conducted at Penn.”

The Katalin Karikó Fellowship Fund in Vaccine Development will provide financial support to an inaugural recipient, who will be awarded later this year, for vaccine research at the Penn Institute for Immunology.

Professor of Medicine Drew Weissman — whose research allowed for the development of the COVID-19 mRNA vaccine — was named the inaugural Roberts Family Professor in Vaccine Research. With the support of the Roberts Family Program, Weissman and his team are working to develop a new vaccine that will protect against the broader classification of coronaviruses.

Karikó, a professor at the Medical School, also worked to develop mRNA technology that was later used in the development of the COVID-19 vaccines administered by Pfizer and Moderna.

“[Karikó and I] knew when we started with this technology that it would be very useful if a pandemic hit because it’s so fast and so easy to make a vaccine with it,” Weissman told the Pennsylvania Gazette.

The professorship and fellowship will attempt to expand the use of mRNA technology and innovative biological approaches to develop vaccines against other infectious diseases.

“The Roberts family has been an exceptional partner in Penn Medicine’s quest to investigate bold approaches that support our vision for the future of health care,” Dean of the Medical School J. Larry Jameson told Penn Medicine News. “[Weissman and Karikó’s] groundbreaking science has inspired the world and now, buoyed by the Roberts family’s tremendous generosity, it has sparked an ambitious research agenda that we are excited to see unfold in the fight against many other infectious diseases and even conditions like cancer.”

https://www.thedp.com/article/2021/08/penn-medicine-professorship-fellowship-mrna-vaccine-research
 
Last edited:
  • Like
Reactions: PEB
Penn scientists win $3 million Breakthrough Prize for RNA research that enabled COVID-19 vaccines
Katalin Kariko and Drew Weissman made a series of pivotal discoveries starting in 2005.

By Tom Avril | Sept. 9, 2021

AMUHMTVO6FCUVMF2NEN5MGCPHU.jpg

Katalin Karikó, left, and Drew Weissman are sharing a $3 million Breakthrough Prize for their mRNA research at the University of Pennsylvania, which enabled the Pfizer-BioNTech and Moderna vaccines against COVID-19.
Sixteen years after their research at the University of Pennsylvania paved the way for billions to be vaccinated against COVID-19, two scientists have been honored with a $3 million Breakthrough Prize.

The award for Katalin Karikó and Drew Weissman, one of five such honors announced Thursday for achievements in science and math, recognizes their success in modifying the genetic molecule called messenger RNA (mRNA) so it can instruct human cells to make customized proteins.

That concept could prove useful in treating all sorts of maladies — years ago, Karikó explored the idea as a therapy for heart disease — but its first widespread success came in teaching the human immune system to fight off the coronavirus. Two of the vaccines, the one made by Moderna and the joint effort from Pfizer and BioNTech, where Karikó now works, rely on mRNA.

In the nine months since the vaccines were authorized for use, preventing untold thousands of hospitalizations and deaths, Karikó and Weissman have won so many awards between them that they’ve lost count. But the Breakthrough Prize, an award sponsored by an international group of tech-industry titans, now in its 10th year, is by far the biggest payoff.

“I never sought any of this,” said Karikó, 66, a senior vice president at BioNTech in Mainz, Germany, who lives part time in Rydal, in Montgomery County, and maintains an adjunct position at Penn. “I went 40 years without any prize.”

“It’s been very wonderful,” said Weissman, 62, a professor at Penn’s Perelman School of Medicine. “I never thought it was possible.”

The scientists said they were grateful for the recognition, and stressed that many others have helped to develop RNA technology since their initial promising results were published in 2005 and 2008.

A slight tweak

Yet before then, the field was seen by many as a dead end. In 1995, for example, Karikó failed to win federal funding for her research and, as a result, was turned down for a tenure-track position at Penn. Still, she stuck with it, working first with cardiologist Elliot Barnathan, then neurosurgeon David Langer, exploring the possibility of using RNA to treat the heart and brain.

But progress was slow. A key roadblock was that RNA, when administered to lab mice, sometimes provoked harmful inflammation.

By the early 2000s, Karikó was collaborating with Weissman, an immunologist, who shared her optimism that there just had to be some way to crack the puzzle. After all, messenger RNA occurs naturally in human cells, carrying vital instructions for the body to make proteins. That code is spelled out with the chemical “bases” taught in every high school biology class, abbreviated A, G, C, and U.

After years of trial and error, the pair found the key. Their laboratory version of mRNA needed just a slight tweak to the molecular structure attached to the “U,” and the inflammation disappeared.

The approach is now being explored as a treatment for all kinds of diseases.

In the vaccines, the mRNA carries the code for a harmless fragment of the coronavirus — its “spike” protein — enabling the recipient’s immune system to practice for a real infection. The platform has the advantage of being readily adaptable as new viral strains emerge, and it also seems to confer stronger protection than other types of vaccines.

Other diseases for which mRNA has shown promise include cystic fibrosis, sickle-cell anemia, and certain cancers. At Children’s Hospital of Philadelphia, researchers have even studied its potential for treating disease before birth.

An early spark
Vindicated after her years of toil, Karikó is delighted to have so many others join the hunt.

Long before she tackled RNA, her scientific curiosity was evident when growing up in small-town Hungary. At age 5, she would observe intently as her father, a butcher, chopped up the carcasses of pigs and rabbits for sale. At area farms she watched, transfixed, as cows gave birth. She made a study of birds’ nests.

“I was climbing, always, the trees,” she said.

Her parents had limited schooling — her mother completed the equivalent of eighth grade, her father sixth — but there was no mistaking their brainpower. Karikó's mother was a skilled bookkeeper, and her father played the violin and could multiply two-digit numbers in his head, she said.

Karikó excelled in school, earning an undergraduate biology degree and a Ph.D. in biochemistry at Hungary’s University of Szeged. She came to Philadelphia in 1985 for a job at Temple University, hiding extra cash inside her daughter’s teddy bear because the Hungarian government allowed the family to emigrate with just $100.

She later worked next at the Uniformed Services University of the Health Sciences in Bethesda, Md., then came back to Philadelphia in 1989 to work at Penn, and still holds an adjunct position there.

Weissman, the son of an engineer and a dental hygienist, also displayed an early aptitude for science, taking apart everything from toasters to doorknobs to see how they worked.

“They were always getting me to put stuff back together,” he said.

As an undergraduate at Brandeis University, he was drawn to the laboratory and majored in biochemistry, then went to Boston University for a Ph.D. in immunology, in 1987. Among his postdoctoral positions was a fellowship at the National Institutes of Health, under infectious-disease chief Anthony Fauci. He came to Penn in 1997.

Among the other Breakthrough Prizes this year are two in the life sciences — one for Jeffery W. Kelly, who studies neurodegenerative disease at Scripps Research Institute, the other split among Shankar Balasubramanian and David Klenerman, both at the University of Cambridge, and Pascal Mayer, chief executive of the French company Alphanosos, for their work on DNA sequencing.

The two other prizes are in math, for Takuro Mochizuki at Kyoto University, and in physics, split between Hidetoshi Katori, of the University of Tokyo and RIKEN, and Jun Ye, of the National Institute of Standards and Technology and the University of Colorado.

The prizes’ founding sponsors are Google cofounder Sergey Brin; Facebook cofounder Mark Zuckerberg and his wife, physician-philanthropist Priscilla Chan; tech investor Yuri Milner and his wife, Julia; and 23andMe founder Anne Wojcicki.

Asked what they would do with their half of the $3 million, Karikó and Weissman both said they would spend some of it on their research. Karikó also pledged to support science education for students who, like her, come from families with limited means. Asked about the coincidence that the prize shared a name with the “breakthrough” infections occurring in some who have been vaccinated, both chuckled ruefully.

Other honors almost certainly are in store. Some in academia predict they will be considered for the biggest prize of all: a Nobel.

In the meantime, the pair remain focused on the science. Karikó is working on a variety of diseases in which patients’ proteins are deficient in some way. Weissman is at work on a vaccine that would protect against multiple coronaviruses, not just the one in this pandemic.

In both cases, they are relying on the approach that already has won them so much acclaim: messenger RNA.

https://www.inquirer.com/health/cor...vaccine-biontech-20210909.html?outputType=amp
 
Last edited:
Penn RNA pioneers snag another big prize for research that enabled COVID-19 vaccines
by Tom Avril | Sept. 24, 2021

7GQZRLA5HBFJBFA6YMU4KW6QJM.jpg
Two University of Pennsylvania scientists have scored another big award for their research on messenger RNA (mRNA), the basis for two COVID-19 vaccines that are credited with saving many thousands of lives.

Katalin Karikó and Drew Weissman are sharing one of 2021′s three Lasker Awards, prize administrators announced Friday. The $250,000 honor comes two weeks after the pair shared a $3 million Breakthrough Prize, and 16 years after their first study that suggested mRNA could be a valuable tool in medicine.

Hundreds of scientists have helped to unlock the promise of this genetic molecule. But when Karikó took on the challenge in the 1990s, RNA research was widely seen as a dead end. The molecules degraded quickly, and, when administered to lab animals, could cause harmful inflammation.

In 2005, she and Weissman reported that by performing a slight chemical modification to the RNA, they made the inflammation all but disappear. That success, followed by others, set the stage for the first two COVID vaccines authorized in the U.S.: the one made by Moderna and the joint effort from Pfizer and BioNTech, where Karikó now works.

J. Larry Jameson, dean of Penn’s Perelman School of Medicine, said the award was an acknowledgment that the duo’s work applies to many diseases besides COVID, such as cancer and sickle-cell anemia.

“From the challenges and losses sown by the COVID-19 pandemic,” he said, “their breakthrough discoveries have emerged and allow us to see a brighter future for so many fields of medicine.”

Weissman, 62, and Karikó, 66, who still holds an adjunct position at Penn, have won more than a dozen awards between them since the dramatic early results were announced for the Pfizer-BioNTech vaccine, less than a year ago.

“I never sought any of this,” Karikó told The Inquirer earlier in September.

Some in academia predict the two are in line for the most prestigious prize of all, a Nobel. That honor typically is awarded years after the impact of research is realized, but the past year has been anything but typical.

This year’s Nobel winners are to be announced the first week of October. If Karikó and Weissman were to be considered for the honor in chemistry or medicine, other RNA researchers likely would be in the mix — though no more than three scientists may share a prize. Some key early advances came from other scientists in the 1980s, and many others came after Karikó and Weissman published two pivotal studies in 2005 and 2008.

“Everyone just incrementally added something — including me,” Karikó told Nature magazine recently.

The power of messenger RNA lies in its ability to deliver genetic instructions for making proteins: the building blocks of life.

In the vaccines, the mRNA prompts the recipient’s cells to make the “spike” protein of the coronavirus, enabling the immune system to safely make antibodies and other defenses in case it ever encounters the actual virus. For treatment of other diseases, mRNA would be used to spur the production of other proteins that patients were unable to make on their own.

After Karikó and Weissman made headway against the inflammation issue, additional research was needed to deliver the delicate genetic instructions inside a living cell. In the vaccines, the approach is to package the mRNA inside tiny, biocompatible droplets made from oily substances called lipids.

The new honor for the Penn duo is called the Lasker-DeBakey Clinical Medical Research Award.

Another Lasker award for basic medical research is going to three scientists who work with light-sensitive proteins: Dieter Oesterhelt of Max Planck Institute of Biochemistry, in Martinsried, Germany; Peter Hegemann of Humboldt University, in Berlin; and Karl Deisseroth of Stanford University.

A third honor, the Lasker-Koshland Special Achievement Award, is going to California Institute of Technology’s David Baltimore, a prominent researcher in immunology and cancer.

The awards are given by the nonprofit Lasker Foundation, established in 1942 by Mary Lasker, a longtime activist in spurring Congress to spend more on medical research, and her husband, advertising executive Albert Lasker.

Weissman and Karikó have said they plan to use some of their prize moneys to support their research. Karikó is among those studying the use of mRNA to treat other diseases. One of Weissman’s projects is improving vaccine equity. For months, he has been working with scientists in Thailand on another mRNA vaccine against COVID.

In August, when the pair got an award from Columbia University, Karikó recalled her reaction last November upon learning that the Pfizer-BioNTech vaccine seemed to prevent more than 90% of cases of disease.

“I celebrated by eating a whole box of Goobers chocolate, which was (first) made 100 years ago in Philadelphia,” she said. “Usually I don’t need the whole box! And of course, I’m not really celebrating until everybody is safe, and the pandemic will end.”

Though Karikó spends much of her time in Mainz, Germany, where BioNTech’s headquarters are located, the two remain in close contact. Soon after the mRNA vaccines were authorized, the pair got vaccinated together in Philadelphia.
https://www.inquirer.com/health/cor...rd-mrna-vaccines-20210924.html?outputType=amp
 
These "prestigious awards" are all so stupid... Whats the reason for them anymore? Fucking Obama won some award for basically nothing and it seems these awards are some kind of insiders club... Grammy, Emmy, Nobel, Redicky... They're all the same and basically worthless...
 
These "prestigious awards" are all so stupid... Whats the reason for them anymore? Fucking Obama won some award for basically nothing and it seems these awards are some kind of insiders club... Grammy, Emmy, Nobel, Redicky... They're all the same and basically worthless...

Don't forget the Noble Prize.

<TheDonald>
 
Hopefully it will be the first one that doesn’t kill the fuck out of everything they give it to.
You think the vaccine for Covid 19 is gonna start killing people? Is there some NWO time release scenario I haven't heard of?
 

Forum statistics

Threads
1,236,401
Messages
55,417,820
Members
174,763
Latest member
ThroughTheDakr
Back
Top